Avidity Biosciences

9 articles with Avidity Biosciences

• Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer

  10/1/2019

  Avidity Biosciences announced the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a member of the Avidity Board of Directors.

• Avidity Biosciences to Present at the 2019 Myotonic Annual Conference

  9/12/2019

  Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic Annual Conference on Saturday, September 14 at 4:00 p.m. ET.

• 

  BioSpace Movers & Shakers, Aug. 23

  8/23/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.

• Avidity Biosciences Adds Drug Development Veterans Edward Kaye and Noreen Henig to Board of Directors

  8/22/2019

  Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and other serious diseases, today announced the appointment of Noreen Henig, M.D., and Edward Kaye, M.D., to the company's board of directors.

• Lilly and Avidity Biosciences Announce Licensing and Research Collaboration

  4/22/2019

  Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties

• 

  Eli Lilly and Avidity Forge Agreement for Immunologic Candidates

  4/22/2019

  The two companies will combine their expertise to drive new immunology candidates toward the clinic.

• Avidity Biosciences' Arthur A. Levin Publishes Review of Therapeutic Approaches of Targeting RNA in the New England Journal of Medicine

  1/3/2019

  Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody- Oligonucleotide Conjugates (AOCs) as a new class of precision medicines, today published a review titled, "Treating Disease at the RNA Level with Oligonucleotides" in the January 3, 2018, issue of the New England Journal of Medicine1.

• Avidity Biosciences Receives Investment from CureDuchenne

  10/17/2018

  Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy

• Avidity Biosciences Raises $16 Million In Series B Financing To Advance Antibody-Sirna Conjugate Platform

  1/5/2017